Advertisement

Reactions Weekly

, Volume 1747, Issue 1, pp 41–41 | Cite as

Antineoplastics/immunosuppressants

Invasive fungal infections: 5 case reports
Case report
Author Information

An event is serious (based on the ICH definition) when the patient outcome is:

  • * death

  • * life-threatening

  • * hospitalisation

  • * disability

  • * congenital anomaly

  • * other medically important event

In a single centre retrospective study of 51 patients who had 18F-fluoro-2-deoxy-D-glucose PET/CT (18F-FDG) between 1 June 2006, and 1 November 2017, 3 men and 2 women aged 31−78 years were described1, who developed lung aspergillosis, pleural empyema, disseminated candidiasis, disseminated trichosporonosis or hepatosplenic candidiasis during treatment with cyclophosphamide, cytarabine, daunorubicin, etoposide, hydroxycarbamide, idarubicin, ifosfamide, lomustine, methotrexate, prednisone, rituximab or vincristine [routes, dosages, durations of treatments to reactions onsets and outcomes not stated].

Patient 6: A 78-year-old man, who had diffuse large B-cell lymphoma, received systemic chemotherapy with R-CHOP regimen consisting of rituximab, cyclophosphamide, daunorubicin,...

Reference

  1. Leroy-Freschini B, et al. 18F-FDG PET/CT for invasive fungal infection in immunocompromised patients. QJM - An International Journal of Medicine 111: 613-622, No. 9, Sep 2018. Available from: URL: http://doi.org/10.1093/qjmed/hcy128 - FranceCrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing AG 2019

Personalised recommendations